Interaction Checker

Acalabrutinib interactions

Acalabrutinib (Calquence) has 86 documented interactions across the FDA labels and fact sheets we index: 78 major, 8 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (78)

  • AmiodaroneantiarrhythmicMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • AtazanavirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • BosentanCYP3A4 inducerMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • CarbamazepineanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • CenobamateanticonvulsantMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • CimetidineH2 blockerMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • ClobazambenzodiazepineMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • CyclosporineimmunosuppressantMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • DarunavirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Deferasiroxiron supplementMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Dexlansoprazoleproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • Diltiazemcalcium channel blockerMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • EfavirenzantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Esomeprazoleproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • EtravirineantiretroviralMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • FamotidineH2 blockerMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • FosamprenavirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • FosphenytoinanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • GriseofulvinantifungalMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Ibuprofen and famotidineNSAIDMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • ImatinibCYP3A4 inhibitorMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • IsoniazidantibioticMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Lansoprazoleproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • LenacapavirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • ModafinilCNS stimulantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Nafcillinpenicillin antibioticMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Naproxen and esomeprazoleNSAIDMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • NefazodoneantidepressantMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • NevirapineantiretroviralMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • NizatidineH2 blockerMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • Omeprazoleproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • Omeprazole and sodium bicarbonateproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Pantoprazoleproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • PerampanelanticonvulsantMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • PrimidoneanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Rabeprazoleproton pump inhibitorMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • RanitidineH2 blockerMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • RifabutinantibioticMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • RifampinantibioticMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • RifapentineantibioticMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • RitonavirantiretroviralMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Sodium bicarbonateantacidMajor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Acalabrutinib label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Ticagrelorantiplatelet agentMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • TopiramateanticonvulsantMajor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (Acalabrutinib label, Drug interactions)

  • Verapamilcalcium channel blockerMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Acalabrutinib label, Drug interactions)

Moderate interactions (8)

  • Antacids (Tums, Maalox, Mylanta)OTC productModerate

    Gastric Acid Reducing Agents Clinical Effect • Co-administration of CALQUENCE with a proton pump inhibitor, H2-receptor antagonist, or antacid may decrease acalabrutinib plasma concentrations [see Clinical Pharmacology (12.3) ] . (Acalabrutinib label, Drug interactions)

  • CalciumVitamin and mineralModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

  • Calcium acetatephosphate binderModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

  • Nimodipinedihydropyridine calcium channel blockerModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (Acalabrutinib label, Drug interactions)

Check Acalabrutinib against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.